| Literature DB >> 26501562 |
Christian Schlenstedt1, Steffen Paschen2, Annika Kruse3, Jan Raethjen2, Burkhard Weisser3, Günther Deuschl2.
Abstract
BACKGROUND: Reduced muscle strength is an independent risk factor for falls and related to postural instability in individuals with Parkinson's disease. The ability of resistance training to improve postural control still remains unclear.Entities:
Mesh:
Year: 2015 PMID: 26501562 PMCID: PMC4621054 DOI: 10.1371/journal.pone.0140584
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1The CONSORT flow diagram for this study.
Participant characteristics.
| Variable | Resistance (n = 17) | Balance (n = 15) |
|
|---|---|---|---|
| Age (yr) | 75.7 ± 5.5 | 75.7 ± 7.2 | 0.882 |
| No. of female subjects | 5 (29.4%) | 6 (40%) | 0.529 |
| Duration of Disease (yr) | 10.1 ± 6.0 | 9.3 ± 7.9 | 0.455 |
| BMI (kg/m2) | 27.9 ± 5.5 | 25.5 ± 4.4 | 0.142 |
| H&Y | 2.8 ± 0.26 | 2.7 ± 0.4 | 0.216 |
| H&Y (Range) | 2.5–3.0 | 2.5–3.0 | n/a |
| UPDRS total (ON) | 40.2 ± 12.5 | 37.7 ± 13.1 | 0.455 |
| UPDRS part II (ON) | 13.4 ± 5.1 | 11.1 ± 6.0 | 0.105 |
| UPDRS part III (ON) | 23.6 ± 9.5 | 22.3 ± 6.1 | 0.941 |
| FAB scale | 22.2 ± 4.8 | 24.5 ± 4.6 | 0.123 |
| MMSE | 27.3 ± 3.6 | 27.7 ± 3.0 | 0.891 |
| MMSE (Range) | 17–30 | 20–30 | n/a |
| PASE score | 104.6 ± 87.3 | 77.2 ± 63.1 | 0.576 |
| LEDD (mg/day) | 817.4 ± 468.0 | 674.7 ± 294.9 | 0.318 |
If not indicated differently, values are either mean ± SD or number and percentage. BMI, Body-Mass-Index; FAB, Fullerton Advanced Balance; H&Y, Hoehn & Yahr; LEDD, levodopa equivalent daily dose; MMSE, Mini-Mental State Examination; PASE, Physical Activity Scale for the Elderly; UPDRS, Unified Parkinson’s Disease Rating Scale
a unless otherwise indicated P-value of independent samples Mann-Whitney-U-Test
b P-value of Chi-Square Test.
Comparison within- and between the two training groups from baseline to 8-weeks follow-up.
| Variable | Baseline | 8-wk follow-up | Mean change (95% CI) from baseline to 8-wk follow-up |
|
| Effect size | Effect size | |
|---|---|---|---|---|---|---|---|---|
| FAB scale | RT | 22.2 ± 4.8 | 24.5 ± 5.4 | 2.4 (0.1; 4.6) | 0.04 | 0.143 | -0.46 | -0.59 |
| BT | 24.5 ± 4.6 | 24.9 ± 5.3 | 0.3 (-0.8; 1.5) | 0.526 | -0.08 | |||
| Forward pull | RT | 2270.3 ± 375.1 | 2336.7 ± 274.0 | 66.4 (-138.2; 270.9) | 0.311 | 0.769 | -0.20 | -0.17 |
| BT | 1807.4 ± 351.8 | 1836.6 ± 360.9 | 29.2 (-66.4; 124.9) | 0.239 | -0.08 | |||
| Backward pull | RT | 1882.3 ± 326.9 | 1782.1 ± 373.4 | -100.2 (-311.5; 111.0) | 0.286 | 0.332 | 0.29 | 0.42 |
| BT | 1844.6 ± 411.4 | 1917.4 ± 362.7 | 72.8 (-261.4; 407.0) | 0.657 | -0.19 | |||
| TUG (sec) | RT | 11.2 ± 3.2 | 9.5 ± 2.4 | -1.7 (-3.3; -0.1) | 0.033 | 0.139 | 0.60 | 0.69 |
| BT | 9.2 ± 3.0 | 9.0 ± 1.8 | -0.2 (-1.3; 0.9) | 0.929 | 0.08 | |||
| UPDRS total score | RT | 40.2 ± 12.5 | 38.5 ± 12.3 | -1.7 (-5.1; 1.8) | 0.347 | 0.272 | 0.14 | -0.38 |
| BT | 37.7 ± 13.1 | 33.6 ± 12.3 | -4.1 (-7.3; -0.9) | 0.033 | 0.32 | |||
| UPDRS motor score | RT | 22.6 ± 8.8 | 22.2 ± 8.9 | -0.4 (-2.0; 1.2) | 0.568 | 0.911 | 0.04 | -0.51 |
| BT | 20.3 ± 4.9 | 19.4 ± 6.7 | -0.9 (-3.0; 1.1) | 0.821 | 0.49 | |||
| gait velocity (cm/sec) | RT | 104.3 ± 15.3 | 106.1 ± 15.0 | 1.8 (-5.2; 8.7) | 0.619 | 0.692 | -0.12 | -0.14 |
| BT | 106.9 ± 18.3 | 106.8 ± 17.7 | -0.1 (-7.4; 7.4) | 0.776 | 0.01 | |||
| stride length (cm) | RT | 80.6 ± 13.0 | 80.3 ± 11.7 | -0.4 (-4.5; 3.7) | 0.865 | 0.097 | 0.02 | 0.50 |
| BT | 88.8 ± 15.7 | 91.5 ± 16.1 | 2.7 (-0.4; 5.9) | 0.131 | -0.17 | |||
| double support time (msec) | RT | 156.6 ± 31.7 | 156.3 ± 35.5 | -0.3 (-8.4; 7.8) | 0.532 | 0.134 | 0.01 | 0.45 |
| BT | 149.4 ± 24.9 | 155.0 ± 32.1 | 5.6 (-2.1; 13.3) | 0.11 | -0.19 | |||
| stride time variability (%) | RT | 3.8 ± 1.0 | 3.7 ± 1.7 | -0.1 (-0.8; 0.6) | 0.334 | 0.413 | 0.07 | -0.53 |
| BT | 3.9 ± 1.8 | 3.0 ± 0.8 | -0.9 (-2.0; 0.3) | 0.182 | 0.65 | |||
| PCI (%) | RT | 6.6 ± 1.5 | 6.1 ± 1.8 | -0.5 (-1.1; 0.1) | 0.061 | 0.077 | 0.30 | 0.75 |
| BT | 6.1 ± 1.4 | 6.9 ± 2.1 | 0.8 (-0.7; 2.3) | 0.286 | -0.45 | |||
| Asymmetry Index | RT | 5.1 ± 4.1 | 6.0 ± 4.3 | 0.9 (-1.1; 0.1) | 0.82 | 0.959 | -0.21 | -0.22 |
| BT | 4.9 ± 3.7 | 5.0 ± 5.3 | 0.1 (-1.6; 1.8) | 0.99 | -0.02 | |||
| leg strength (MVC), LES (N) | RT | 393.8 ± 113.5 | 416.9 ± 91.0 | 23.0 (-15.5; 61.6) | 0.279 | 0.458 | -0.22 | -0.43 |
| BT | 416.5 ± 129.6 | 408.8 ± 138.5 | -7.7 (-53.3; 37.8) | 0.925 | 0.06 | |||
| leg strength (MVC), MAS (N) | RT | 401.8 ± 130.0 | 399.8 ± 85.7 | -2.0 (-48.2; 44.2) | 0.807 | 0.287 | 0.02 | 0.33 |
| BT | 407.9 ± 134.4 | 426.2 ± 131.6 | 18.3 (-4.4; 41.1) | 0.133 | -0.14 | |||
| peak RFD, LAS (N/msec) | RT | 1.5 ± 0.7 | 1.6 ± 0.8 | 0.1 (-0.4; 0.4) | 0.753 | 0.223 | -0.13 | 0.50 |
| BT | 1.6 ± 1.0 | 1.8 ± 0.9 | 0.3 (0.0; 0.5) | 0.028 | -0.21 | |||
| peak RFD, MAS (N/msec) | RT | 1.5 ± 1.0 | 1.5 ± 0.7 | 0.0 (-0.6; 0.5) | 0.972 | 0.503 | 0.00 | 0.40 |
| BT | 1.4 ± 0.7 | 1.7 ± 0.9 | 0.3 (-0.2; 0.8) | 0.308 | -0.37 | |||
| RFD, LAS (N/msec) | RT | 0.8 ± 0.6 | 0.9 ± 0.6 | 0.1 (-0.2; 0.5) | 0.249 | 0.627 | -0.17 | 0.31 |
| BT | 0.7 ± 0.5 | 1.0 ± 0.6 | 0.3 (0.0; 0.5) | 0.056 | -0.54 | |||
| RFD, MAS (N/msec) | RT | 0.8 ± 0.7 | 0.9 ± 0.6 | 0.1 (-0.3; 0.5) | 0.600 | 0.939 | -0.15 | -0.14 |
| BT | 0.9 ± 0.7 | 0.9 ± 0.7 | 0.0 (-0.4; 0.4) | 0.507 | 0.00 |
FAB, Fullerton Advanced Balance; TUG, Timed-Up-and-Go-Test; LAS, less affected side; MAS, more affected side; MVC, maximal voluntary contraction; PCI, Phase Coordination Index; RFD, rate of force development (0-100ms); UPDRS, Unified Parkinson’s Disease Rating Scale
a p-value of Wilcoxon test
b p-value of independent samples Mann-Whitney-U-Test
c Cohen’s d was calculated as effect size
d blinded video rating
e values represent the area under the curve of the normalized vector length from 0–3 sec after the surface perturbation
f blinded video rating, without item 22 (rigidity)
RT, resistance training (n = 17); BT, balance training (n = 15)
*significant different (p<0.05)
**after Bonferroni-adjustment not significant.
Fig 2Average normalized center of mass (COM) vector length of one participant during backward perturbations at baseline and 8-weeks follow-up.
Fig 3Results of the Clinical Global Impression–Improvement scale (CGI-I).
Comparison of baseline, 8- and 12-weeks follow-up.
| Variable | Group | Baseline | 8-wk follow-up | 12-wk follow-up | Mean change (baseline to 12-wk follow-up) (95% CI) |
|
|
|---|---|---|---|---|---|---|---|
| FAB scale | RT | 22.2 ± 5.3 | 24.4 ± 5.7 | 22.5 ± 5.1 | 0.3 (-2.2; 2.8) | 0.370 | 0.767 |
| BT | 24.8 ± 4.2 | 25.3 ± 4.4 | 24.0 ± 4.6 | -0.8 (-2.6; 1.0) | 0.900 | ||
| TUG (sec) | RT | 11.4 ± 3.6 | 9.4 ± 2.5 | 10.0 ± 2.1 | -1.4 (-3.2; 0.4) | 0.686 | 0.699 |
| BT | 9.2 ± 3.8 | 9.0 ± 2.4 | 8.4 ± 1.9 | -0.8 (-3.5; 1.9) | 0.139 | ||
| UPDRS total score | RT | 40.7 ± 15.0 | 40.7 ± 13.1 | 39.4 ± 12.0 | -1.4 (-9.8; 7.1) | 0.183 | 0.797 |
| BT | 38.8 ± 14.7 | 32.8 ± 13.5 | 36.4 ± 15.9 | -2.5 (-9.0; 4.1) | 0.286 | ||
| UPDRS motor score | RT | 23.7 ± 10.4 | 23.4 ± 10.5 | 22.5 ± 10.2 | -1.2 (-3.3; 0.9) | 0.183 | 0.833 |
| BT | 20.8 ± 4.1 | 19.3 ± 6.6 | 19.6 ± 5.5 | -1.3 (-3.4; 0.9) | 0.052 |
FAB, Fullerton Advanced Balance; TUG, Timed-Up-and-Go-Test; UPDRS, Unified Parkinson’s Disease Rating Scale
a p-value of Wilcoxon test
b p-value of independent samples Mann-Whitney-U-Test
c blinded video rating
d blinded video rating, without item 22 (rigidity)
RT, resistance training (n = 14); BT, balance training (n = 11).
Correlation between the differences from baseline to 8-weeks follow-up of the FAB scale with the differences from baseline to 8-weeks follow-up of other outcomes.
| Resistance | Balance | |||
|---|---|---|---|---|
| Variable | Rho |
| Rho |
|
| Forward pull | -0.318 | 0.289 | -0.366 | 0.241 |
| Backward pull | -0.217 | 0.420 | 0.019 | 0.956 |
| TUG | -0.097 | 0.754 | 0.230 | 0.497 |
| UPDRS total score | -0.413 | 0.100 | 0.003 | 0.992 |
| UPDRS motor score | -0.397 | 0.115 | 0.030 | 0.915 |
| gait velocity | 0.148 | 0.572 | 0.058 | 0.837 |
| stride length | 0.319 | 0.246 | -0.074 | 0.828 |
| double support time | 0.310 | 0.260 | -0.357 | 0.281 |
| stride time variability |
|
| 0.260 | 0.440 |
| PCI | -0.152 | 0.587 |
|
|
| Asymmetry Index | 0.215 | 0.441 | -0.153 | 0.653 |
| Leg Strength (MVC), LAS | 0.014 | 0.964 | 0.343 | 0.230 |
| Leg Strength (MVC), MAS | -0.510 | 0.075 | -0.140 | 0.647 |
| peak RFD, LAS | 0.114 | 0.712 | -0.003 | 0.993 |
| peak RFD, MAS | 0.263 | 0.385 | -0.119 | 0.713 |
| average RFD (0-100ms), LAS |
|
| 0.276 | 0.340 |
| average RFD (0-100ms), MAS | 0.355 | 0.235 | -0.174 | 0.569 |
| PDQ-39 | 0.017 | 0.948 | 0.053 | 0.852 |
| BDI | 0.337 | 0.186 |
|
|
BDI, Beck Depression Inventory; FAB, Fullerton Advanced Balance; TUG, Timed-Up-and-Go-Test; LAS, less affected side; MAS, more affected side; MVC, maximal voluntary contraction; PCI, Phase Coordination Index; PDQ-39, Parkinson’s Disease Questionnaire; RFD, rate of force development; UPDRS, Unified Parkinson’s Disease Rating Scale
a Spearman’s rank correlation coefficient
b value represents the area under the curve of the normalized vector length from 0–3 sec after the surface perturbation (see Fig 2 and S3 File)
c blinded video rating, without item 22 (rigidity).